Celltrion Hits Record Q3 Earnings on New Biosimilars

Celltrion, a leading biopharmaceutical company, experienced a record third quarter with revenue soaring 53.1% year over year to a whopping 1.58 trillion won ($1.18 billion). Operating profit followed suit, jumping 74.3% to 525.3 billion won. These impressive figures exceeded analyst estimates by 8.6% and 3.1%, respectively. The company's operating profit margin reached a notable 33.3%, marking a 4.0 percentage point improvement from the previous year.

This surge in profitability can be attributed to the successful launch of five new biosimilar products, including Steqeyma, Omlyclo, Eydenzelt, Stoboclo, and Osenvelt, collectively generating 388 billion won in sales, a staggering 335% year-over-year increase. Omlyclo, in particular, made significant waves, securing a 30% market share just a year after its European debut and generating 132.1 billion won in revenue.

The product's success led to a supply agreement with a major healthcare company and placement on a pharmacy benefit manager's preferred drug formulary in the United States. Other products, such as Stoboclo and Osenvelt, contributed significantly to revenue growth, with combined sales of 112.2 billion won, up 52.7% quarter-on-quarter.

This surge in revenue and profitability can be attributed to the strong performance of new biosimilars and an improved product mix, signaling a shift away from legacy products. Following the strong results, several brokerage firms raised their price targets for Celltrion, reflecting confidence in the company's rapid growth in new biosimilars and improving profitability.

Analysts also noted that Celltrion's operating profit margin is projected to reach 36.2% next year, surpassing the estimated 10% to 20% range for competitors, indicating a strong competitive advantage.